Fidelity Select Pharmaceuticals
FPHAX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 245 Summer Street Boston MA United States of America 2210
- IPO Date
- Jun 18, 2001
- CIK
- 0000320351
- Website
- fundresearch.fidelity.com
- Similar Companies
- Business
- Fidelity Select Pharmaceuticals Portfolio (FPHAX) is an open-end mutual fund that normally invests at least 80% of its assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types; it primarily invests in common stocks of domestic and foreign issuers, employing fundamental analysis of issuers' financial condition, industry position, market, and economic conditions. The fund targets the health care sector, with a focus on large-cap growth stocks in pharmaceuticals and biotechnology; top holdings typically include Eli Lilly and Co., AstraZeneca PLC, Novo Nordisk A/S, Merck & Co Inc., and Gilead Sciences Inc., among others representing biotechnology, specialty pharmaceuticals, and animal health products. It operates globally, with significant exposure to U.S., European, and other international markets, and is non-diversified. Launched on June 18, 2001, the fund is managed by Fidelity Investments, headquartered at 82 Devonshire Street, Boston, Massachusetts. As of late 2025, the fund maintains assets under management of approximately $1.12 billion, with a net expense ratio of 0.67%, and is led by portfolio manager Karim Suwwan de Felipe since July 2017. Recent developments include Fidelity's proposals in June and July 2025 for mergers involving five Select sector funds, approved by the Equity and High Income Board of Trustees, with prospectuses supplemented on July 22, 2025, to outline shareholder impacts and policy adjustments such as converting certain investment policies to fundamental status requiring future shareholder approval; additionally, portfolio activity highlighted in mid-2025 updates featured overweight positions in Elanco Animal Health following new product launches enhancing competitiveness against peers like Zoetis, and Avidity Biosciences benefiting from U.S. FDA Breakthrough Therapy designation in August for its Duchenne muscular dystrophy candidate, alongside ongoing readouts and potential blockbuster launches in oncology, metabolic, and respiratory areas from key holdings.